<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Form Res</journal-id><journal-id journal-id-type="publisher-id">formative</journal-id><journal-id journal-id-type="index">27</journal-id><journal-title>JMIR Formative Research</journal-title><abbrev-journal-title>JMIR Form Res</abbrev-journal-title><issn pub-type="epub">2561-326X</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v10i1e94551</article-id><article-id pub-id-type="doi">10.2196/94551</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Evaluating the Impact and Practicality of a National Digital Intervention for Type 2 Diabetes Mellitus: Single-Arm Nonrandomized Pilot Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yong</surname><given-names>Alice Moi Ling</given-names></name><degrees>MBChB</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chan</surname><given-names>Hiu Nam</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chong</surname><given-names>Pui Lin</given-names></name><degrees>MBChB</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yung</surname><given-names>Chee Kwang</given-names></name><degrees>MBChB</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mulok</surname><given-names>Musjarena</given-names></name><degrees>MSc, MBBS</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Musa</surname><given-names>Syuhrah</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chan</surname><given-names>Si Yee</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names>Yvonne</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yusof</surname><given-names>Athirah</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names>Yufan</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lim</surname><given-names>Hong Shen</given-names></name><degrees>MBBS</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><institution>Endocrine Centre, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital</institution><addr-line>Jalan Putera Al-Muhtadee Billah</addr-line><addr-line>Bandar Seri Begawan</addr-line><country>Brunei Darussalam</country></aff><aff id="aff2"><institution>EVYD Research Pte Ltd</institution><addr-line>Singapore</addr-line><country>Singapore</country></aff><aff id="aff3"><institution>Department of Health Services, Ministry of Health</institution><addr-line>Bandar Seri Begawan</addr-line><country>Brunei Darussalam</country></aff><aff id="aff4"><institution>EVYD Technology Sdn Bhd</institution><addr-line>Bandar Seri Begawan</addr-line><country>Brunei Darussalam</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Mavragani</surname><given-names>Amaryllis</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Steenstra</surname><given-names>Ivan</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Hartanto</surname><given-names>Andree</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Alice Moi Ling Yong, MBChB, Endocrine Centre, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital, Jalan Putera Al-Muhtadee Billah, Bandar Seri Begawan, BA1712, Brunei Darussalam, +673 2242424; <email>alice.yong@moh.gov.bn</email></corresp></author-notes><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2026</year></pub-date><volume>10</volume><elocation-id>e94551</elocation-id><history><date date-type="received"><day>03</day><month>03</month><year>2026</year></date><date date-type="rev-recd"><day>18</day><month>06</month><year>2026</year></date><date date-type="accepted"><day>18</day><month>06</month><year>2026</year></date></history><copyright-statement>&#x00A9; Alice Moi Ling Yong, Hiu Nam Chan, Pui Lin Chong, Chee Kwang Yung, Musjarena Mulok, Syuhrah Musa, Si Yee Chan, Yvonne Lee, Athirah Yusof, Yufan Chen, Hong Shen Lim. Originally published in JMIR Formative Research (<ext-link ext-link-type="uri" xlink:href="https://formative.jmir.org">https://formative.jmir.org</ext-link>), 29.7.2026. </copyright-statement><copyright-year>2026</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://formative.jmir.org">https://formative.jmir.org</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://formative.jmir.org/2026/1/e94551"/><abstract><sec><title>Background</title><p>Type 2 diabetes mellitus (T2DM) requires sustained self-management and lifestyle modification to achieve optimal glycemic control. Hybrid care models that combine digital health technologies with in-person clinical support may enhance patient engagement while improving the accessibility and scalability of diabetes care. However, evidence regarding their effectiveness and feasibility in Southeast Asian populations remains limited.</p></sec><sec><title>Objective</title><p>This study aimed to evaluate the preliminary effectiveness and feasibility of a national hybrid digital intervention for individuals with T2DM in Brunei Darussalam. The primary objective was to evaluate the proportion of participants achieving a reduction in glycated hemoglobin (HbA<sub>1c</sub>) of &#x2265;0.6% after 16 weeks. Secondary objectives included evaluating changes in metabolic parameters, anthropometric outcomes, and health-related quality of life (QoL).</p></sec><sec sec-type="methods"><title>Methods</title><p>This single-arm, nonrandomized pilot trial enrolled adults with T2DM into a 16-week hybrid digital intervention integrating remote health coaching, structured digital education, self-monitoring activities, and asynchronous communication via WhatsApp. Participants attended scheduled video consultations (VCs) and submitted self-monitoring records throughout the intervention period. Clinical outcomes included changes in HbA<sub>1c</sub>, fasting blood glucose, lipid profile parameters, BMI, waist circumference, and QoL measured using the EQ-5D-5L instrument. Feasibility outcomes included intervention completion, VC attendance, participant engagement, and intervention acceptability.</p></sec><sec sec-type="results"><title>Results</title><p>A total of 122 participants were enrolled, and 108 (88.5%) completed the intervention. Among 104 participants with complete HbA<sub>1c</sub> data, there was a mean reduction of 1.2% (95% CI &#x2212;1.45 to &#x2212;0.96; <italic>P</italic>&#x003C;.001). Overall, 65.4% (68/104) of participants achieved the predefined HbA<sub>1c</sub> reduction threshold of &#x2265;0.6%, while 84.6% (88/104) demonstrated an overall reduction in HbA<sub>1c</sub>. Significant improvements were also observed in fasting blood glucose (&#x2212;1.7 mmol/L, 95% CI &#x2212;2.3 to &#x2212;1.2; <italic>P</italic>&#x003C;.001), BMI (&#x2212;0.4 kg/m&#x00B2;, 95% CI &#x2212;0.6 to &#x2212;0.2; <italic>P</italic>&#x003C;.001), waist circumference (&#x2212;1.9 cm, 95% CI &#x2212;2.9 to &#x2212;0.9; <italic>P</italic>&#x003C;.001), total cholesterol (&#x2212;0.3 mmol/L, 95% CI &#x2212;0.6 to &#x2212;0.2; <italic>P</italic>&#x003C;.001), triglycerides (&#x2212;0.5 mmol/L, 95% CI &#x2212;0.7 to &#x2212;0.2; <italic>P</italic>&#x003C;.001), and EuroQol Visual Analog Scale (EQ-VAS) scores (+6.7 points, 95% CI 3.9 to 9.6; <italic>P</italic>&#x003C;.001). The intervention demonstrated favorable feasibility outcomes, including an 88.5% (108/122) completion rate, attendance at &#x2265;5 VCs by 75.9% (82/108) of participants, and high participant satisfaction, with 86.9% (86/99) of respondents reporting satisfaction or extreme satisfaction with the intervention.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The pilot trial demonstrated the acceptability, preliminary effectiveness, and feasibility of a national hybrid digital intervention for individuals with T2DM in Brunei Darussalam. High completion rates, sustained participant engagement, and positive participant feedback support the practicality of implementation within a national digital health ecosystem. The intervention was also associated with improvements in glycemic control, metabolic outcomes, anthropometric measures, and health-related QoL. Larger controlled studies are warranted to evaluate long-term effectiveness, scalability, and implementation outcomes.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov NCT05364476; https://clinicaltrials.gov/study/NCT05364476</p></sec></abstract><kwd-group><kwd>type 2 diabetes mellitus</kwd><kwd>telemedicine</kwd><kwd>intervention</kwd><kwd>lifestyle modification</kwd><kwd>quality of life</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><sec id="s1-1"><title>Background</title><p>Type 2 diabetes mellitus (T2DM) remains one of the leading global public health challenges and is associated with substantial morbidity, premature mortality, and reduced quality of life (QoL) [<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref>]. Effective diabetes management requires sustained lifestyle management, including dietary modification, regular physical activity, weight management, and self-monitoring behaviors to improve glycemic outcomes and reduce diabetes-related complications [<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref>]. However, consistent long-term delivery of this routine clinical practice into interventions remains difficult due to limited health care resources, workforce constraints, and dependence on repeated face-to-face counseling [<xref ref-type="bibr" rid="ref5">5</xref>].</p><p>The rapid expansion of digital health technologies, particularly with the COVID-19 pandemic, has accelerated the adoption of digital therapeutics (DTx) and mobile health (mHealth) interventions for chronic disease management. DTx are evidence-based therapeutic interventions driven by software programs to prevent, manage, or treat medical disorders [<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref>]. In T2DM management, digital interventions commonly incorporate the use of smartphone apps, wearable devices for monitoring, telehealth consultations, remote monitoring, and personalized health coaching to support self-management and improve active patient engagement [<xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref9">9</xref>].</p><p>Digital health interventions have increasingly demonstrated potential to improve glycemic outcomes and diabetes self-management among individuals with T2DM. Systematic reviews evaluating mHealth applications, telemonitoring, and technology-enabled diabetes self-management interventions have reported improvements in glycated hemoglobin (HbA<sub>1c</sub>), self-management behaviors, and patient engagement [<xref ref-type="bibr" rid="ref8">8</xref>-<xref ref-type="bibr" rid="ref10">10</xref>]. Hybrid care approaches integrating remote support with lifestyle education have additionally shown potential to improve accessibility and continuity of chronic disease management [<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref>].</p><p>Despite increasing evidence in support of DTx for T2DM management, implementation in Southeast Asia and Muslim-majority countries remains limited. Variations in digital literacy, cultural practices, health care infrastructure, and patient engagement behaviors influence the feasibility and effectiveness of digital interventions across populations. Consequently, real-world implementation studies are needed to evaluate the applicability and preliminary effectiveness of DTx within localized health care systems.</p><p>Brunei Darussalam is a small Southeast Asian country with a population of approximately 450,000 and universal access to government-funded health care services [<xref ref-type="bibr" rid="ref13">13</xref>]. Despite this, diabetes and related metabolic risk factors remain a significant public health concern. Recent national surveillance data estimated that 15% of adults are living with diabetes, highlighting the substantial disease burden within the local population. In addition, diabetes is one of the leading causes of death, placing considerable strain on long-term health care utilization and economic resources [<xref ref-type="bibr" rid="ref14">14</xref>].</p><p>Brunei&#x2019;s national mobile app, BruHealth, has evolved from a COVID-19 contact tracing tool into a nationwide digital population health platform capable of supporting access to personal health records and health navigation features such as appointment booking. This digital infrastructure provides an opportunity to support scalable and accessible DTx delivery for T2DM management within the Bruneian health care system while potentially reducing reliance on in-person consultations and optimizing health system use.</p><p>Evidence evaluating the feasibility and effectiveness of integrated digital diabetes interventions in Brunei remains limited. The DEsireD (Development and Exploration of Effectiveness and Feasibility of Digital Intervention for Type 2 Diabetes Mellitus) study was designed to evaluate a hybrid digital intervention integrating remote health coaching, structured educational support, and self-monitoring activities for individuals with T2DM in Brunei Darussalam [<xref ref-type="bibr" rid="ref15">15</xref>].</p></sec><sec id="s1-2"><title>Aims of This Study</title><p>This study aimed to evaluate the preliminary effectiveness and feasibility of a hybrid digital intervention for individuals with T2DM in Brunei Darussalam. The intervention combined digital lifestyle management delivered online with offline health coaching and monitoring support.</p><p>The primary objective was to evaluate the proportion of participants achieving a reduction in HbA<sub>1c</sub> of &#x2265;0.6% after 16 weeks of sustained lifestyle modifications administered through a digital intervention. Secondary objectives included evaluating changes in metabolic parameters, including fasting blood glucose (FBG) and lipid profile parameters (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides); anthropometric parameters, including BMI and waist circumference; and health-related QoL measured using the EQ-5D-5L instrument.</p></sec></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study Design</title><p>This study was a single-arm, nonrandomized pilot trial evaluating the feasibility and effectiveness of a hybrid digital intervention for individuals with T2DM in Brunei Darussalam. The intervention combined remote health coaching, structured digital education, and self-monitoring activities delivered through WhatsApp-supported communication. Participants were instructed to continue their existing medications throughout the study period, and no changes to prescribed treatments were made as part of the intervention; however, clinically indicated adjustments were permitted in cases of recurrent hypoglycemia for patient safety. The detailed study methodology has been published previously [<xref ref-type="bibr" rid="ref15">15</xref>].</p></sec><sec id="s2-2"><title>Recruitment</title><p>Participants were recruited through both online and offline outreach methods. Online recruitment included in-app banners and push notifications within the BruHealth app, and social media advertisements. Offline recruitment involved flyer distribution, banners, posters displayed at health centers, and radio broadcasts.</p><p>Interested individuals were invited to contact the study team for further information and eligibility screening. Written informed consent was obtained from all participants before participation in the study.</p></sec><sec id="s2-3"><title>Eligibility Criteria</title><p>Eligibility criteria were established to identify adults with suboptimally controlled T2DM who were suitable for participation in a lifestyle-based digital intervention study. Exclusion criteria were established to minimize safety risks and ensure suitability for participation in a remotely delivered lifestyle intervention.</p><p><xref ref-type="other" rid="box1">Textbox 1</xref> summarizes the study inclusion and exclusion criteria.</p><boxed-text id="box1"><title> Study inclusion and exclusion criteria.</title><p><bold>Inclusion criteria</bold></p><list list-type="bullet"> <list-item><p>Diagnosed with type 2 diabetes mellitus</p></list-item> <list-item><p>HbA<sub>1c</sub> (glycated hemoglobin) &#x2265;7% within the previous 12 months</p></list-item> <list-item><p>Aged 20-70 years</p></list-item> <list-item><p>BMI 23-50 kg/m&#x00B2;</p></list-item> </list><p><bold>Exclusion criteria</bold></p><list list-type="bullet"> <list-item><p>Pregnancy or breastfeeding</p></list-item> <list-item><p>Insulin or injectable noninsulin therapy use</p></list-item> <list-item><p>History of hypoglycemic or hyperglycemic crisis within the previous 6 months</p></list-item> <list-item><p>Blood pressure &#x2265;160/100 mm Hg</p></list-item> <list-item><p>Recurrent acute pancreatitis</p></list-item> <list-item><p>Decompensated liver cirrhosis</p></list-item> <list-item><p>Estimated glomerular filtration rate &#x003C;60 mL/min/1.73 m&#x00B2;</p></list-item> <list-item><p>Recent cardiovascular or cerebrovascular events within the previous 12 months</p></list-item> <list-item><p>Arrhythmias or New York Heart Association class II-IV heart failure</p></list-item> <list-item><p>Proliferative diabetic retinopathy</p></list-item> <list-item><p>Foot ulcer or gangrene</p></list-item> <list-item><p>Deep vein thrombosis or intermittent claudication</p></list-item> <list-item><p>Active cancer</p></list-item> <list-item><p>Posttransplant status or planned surgery within 6 months</p></list-item> <list-item><p>Thyroid disorders including subclinical disease</p></list-item> <list-item><p>Musculoskeletal conditions limiting physical activity</p></list-item> <list-item><p>Inability to perform activities of daily living</p></list-item> <list-item><p>Inability to use mobile social media apps (eg, WhatsApp and YouTube)</p></list-item> </list></boxed-text></sec><sec id="s2-4"><title>Intervention Delivery</title><p>Participants enrolled in a 16-week hybrid digital intervention study that provided both structured digital education and offline diabetes management support provided by health care personnel. These health care personnel underwent modular training specific to the study protocol, including diabetes self-management education, communication workflows, participant engagement procedures, and escalation processes. The clinical study team consisted of health coaches, dietitians, general practitioner<strike>s</strike>, and endocrinologists who collaboratively supported monitoring and follow-up throughout the intervention period. Detailed intervention workflows, escalation procedures, and multidisciplinary operational structures and roles have been described previously in the published DEsireD protocol paper [<xref ref-type="bibr" rid="ref15">15</xref>].</p><p>Communication between participants and health coaches was conducted primarily through WhatsApp via text messages, video consultations (VCs), reminders, and submission of self-monitoring records. Participants attended a total of 7 scheduled VCs throughout the 16-week intervention period.</p><p>Weekly digital educational materials were provided through multimedia materials shared via WhatsApp and Google Drive links. Educational content focused on diabetes self-management, exercise planning, healthy dietary methods, blood glucose monitoring, and SMART (Specific, Measurable, Achievable, Relevant, and Time-bound) goal setting.</p><p>Participants self-reported dietary intake, physical activity, body weight, and waist circumference logs using paper-based diary cards. Completed records were submitted weekly by photographing and sharing the diary cards with health coaches through WhatsApp. Dietary and physical activity recommendations were provided during consultations, through participant-initiated WhatsApp inquiries, or through self-directed learning from educational materials. Participant progress, adherence, and records were reviewed through a biweekly reporting workflow between all operational personnel to support monitoring, participant follow-up, and escalation where required.</p><p>To support participant engagement with the study and facilitate sustained participation throughout the intervention, weekly reminders for diary card submission were sent every Monday through WhatsApp. Additional reminders for scheduled consultations were sent 3 days and 1 day before each consultation. To further ensure seamless digital communication, participants were provided mobile data support throughout the study period.</p></sec><sec id="s2-5"><title>Outcome Measures</title><p>The primary outcome was the proportion of participants achieving a HbA<sub>1c</sub> reduction of &#x2265;0.6% following the 16-week intervention. A reduction threshold of &#x2265;0.6% was selected based on prior mHealth and digital intervention literature and studies reporting weighted mean HbA<sub>1c</sub> reductions ranging from &#x2212;0.4% to &#x2212;0.9% [<xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref16">16</xref>].</p><p>Secondary outcomes were to evaluate changes in metabolic parameters, including FBG and lipid profile parameters (total cholesterol, LDL-C, HDL-C, and triglycerides); changes in anthropometric parameters, including BMI and waist circumference; and health-related QoL measured using the EQ-5D-5L instrument.</p><p>Feasibility and engagement outcomes included intervention completion, attendance at scheduled VCs, submission of self-monitoring records throughout the intervention period, and participant satisfaction with the intervention.</p></sec><sec id="s2-6"><title>Statistical Analysis</title><p>Statistical analyses were performed using GraphPad Prism software (GraphPad Software Inc). Continuous variables were presented as mean (SD), while categorical variables were presented as frequencies and percentages. Analyses for each outcome were performed using available participant data at both baseline and end point. Changes between baseline and end point outcomes were evaluated using paired 2-tailed <italic>t</italic> tests for continuous variables. Changes in paired categorical EQ-5D-5L domain outcomes between baseline and end point assessments were evaluated using McNemar tests.</p><p>As this study was conducted as a clinical trial involving multiple outcome measures, a more stringent threshold for statistical significance (<italic>P</italic>&#x003C;.001) was applied to enhance the robustness of the findings and reduce the likelihood of type I error arising from multiple comparisons. Based on this prespecified significance threshold, findings with <italic>P</italic> values &#x2265;.001 and &#x003C;.05 were interpreted as not meeting the predefined threshold for statistical significance.</p></sec><sec id="s2-7"><title>Ethical Considerations</title><p>The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines as defined by the International Council for Harmonization. Ethical approval was obtained from the Medical and Health Research and Ethics Committee, Ministry of Health, Brunei Darussalam (reference number: MHREC/MOH/2022/4[1]).</p><p>All participants received a participant information sheet detailing the study procedures, interventions, and potential risks prior to enrollment. Written informed consent was obtained from all participants before participation in the study. Participants were informed that their participation was voluntary and that they could withdraw from the study at any time without affecting their standard medical care.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Participant Flow and Baseline Characteristics</title><p>A total of 122 participants were enrolled in the study. During the 16-week intervention period, 10 (8.2%) participants withdrew from the study. Four (3.3%) participants did not attend any health coach VCs but were still included in baseline and end point analyses. Overall, 108 (88.5%) participants completed the intervention. The participant flow from eligibility assessment to outcome analysis is shown in <xref ref-type="fig" rid="figure1">Figure 1</xref>.</p><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>CONSORT (Consolidated Standards of Reporting Trials)-style participant flow diagram. <sup>a</sup>LDL-C and HDL-C values were unavailable for 2 participants because of elevated triglyceride levels precluding calculation. One participant did not complete end point FBG assessment, and 1 participant did not submit end point anthropometric measurements. DM180: Diabetes management 180; FBG: fasting blood glucose; LDL-C: low-density lipoprotein cholesterol; HbA<sub>1c</sub>: glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="formative_v10i1e94551_fig01.png"/></fig><p>Primary HbA<sub>1c</sub> outcomes were available for 104 participants. Four participants who completed the intervention did not complete the postintervention HbA<sub>1c</sub> assessment and were excluded from the primary outcome analysis. For secondary outcomes, FBG data were available for 103 participants because 1 participant did not complete end point FBG assessment. BMI and waist circumference data were available for 103 participants because 1 participant did not submit end point anthropometric measurements. LDL-C and HDL-C data were available for 102 participants because values could not be calculated in 2 participants due to elevated triglyceride levels. Reasons for dropout included nonstudy-related injury, pregnancy, personal commitments, and one nondiabetes-related hospitalization.</p><p><xref ref-type="table" rid="table1">Table 1</xref> summarizes participant baseline characteristics. The mean age of participants was 43.0 (SD 9.3) years, and 45.1% (55/122) of participants were male. The distribution of participants by age group and sex is presented in <xref ref-type="supplementary-material" rid="app1">Multimedia Appendix 1</xref>. Most participants had been diagnosed with T2DM for less than 10 years (92/122, 75.4%). Most participants were receiving oral hypoglycemic therapy in addition to lifestyle management.</p><table-wrap id="t1" position="float"><label>Table 1.</label><caption><p>Baseline demographics of participants (N=122).</p></caption><table id="table1" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Characteristic</td><td align="left" valign="bottom">Value</td></tr></thead><tbody><tr><td align="left" valign="top">Age (y), mean (SD)</td><td align="left" valign="top">43.0 (9.3)</td></tr><tr><td align="left" valign="top" colspan="2">Sex, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Male</td><td align="left" valign="top">55 (45.1)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Female</td><td align="left" valign="top">67 (54.9)</td></tr><tr><td align="left" valign="top" colspan="2">Duration of T2DM<sup><xref ref-type="table-fn" rid="table1fn1">a</xref></sup>, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Diagnosis of &#x003C;10 y</td><td align="left" valign="top">92 (75.4)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Diagnosis of &#x2265;10 y</td><td align="left" valign="top">30 (24.6)</td></tr><tr><td align="left" valign="top" colspan="2">Treatment regimen, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Lifestyle management only</td><td align="left" valign="top">3 (2.5)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Lifestyle management and 1 OHA<sup><xref ref-type="table-fn" rid="table1fn2">b</xref></sup></td><td align="left" valign="top">31 (25.4)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Lifestyle management and 2 OHA</td><td align="left" valign="top">47 (38.5)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Lifestyle management and &#x2265;3 OHA</td><td align="left" valign="top">30 (24.6)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Missing medication data</td><td align="left" valign="top">11 (9)</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>T2DM: type 2 diabetes mellitus.</p></fn><fn id="table1fn2"><p><sup>b</sup>OHA: oral-hypoglycemic agent.</p></fn></table-wrap-foot></table-wrap><p>Sex-stratified baseline anthropometric characteristics are additionally summarized in <xref ref-type="supplementary-material" rid="app2">Multimedia Appendix 2</xref>.</p></sec><sec id="s3-2"><title>Primary Outcome</title><p>Among 104 participants with complete HbA<sub>1c</sub> data, mean HbA<sub>1c</sub> decreased from 8.8% (SD 1.2) at baseline to 7.6% (SD 1.1) following the 16-week intervention. This represented a mean reduction of &#x2212;1.2% (95% CI &#x2212;1.43 to &#x2212;0.93; <italic>P</italic>&#x003C;.001). A total of 65.4% (68/104) of participants achieved the predefined HbA<sub>1c</sub> reduction threshold of &#x2265;0.6% (95% CI 55.4%&#x2010;74.4%). <xref ref-type="table" rid="table2">Table 2</xref> summarizes the primary HbA<sub>1c</sub> outcomes following the intervention.</p><table-wrap id="t2" position="float"><label>Table 2.</label><caption><p>Primary glycemic outcomes following the intervention (N=104).</p></caption><table id="table2" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Category</td><td align="left" valign="bottom">Value</td></tr></thead><tbody><tr><td align="left" valign="top">Participants achieving HbA<sub>1c</sub><sup><xref ref-type="table-fn" rid="table2fn1">a</xref></sup> reduction &#x2265;0.6%, n (%)</td><td align="left" valign="top">68 (65.4)</td></tr><tr><td align="left" valign="top">Participants with overall HbA<sub>1c</sub> reduction, n (%)</td><td align="left" valign="top">88 (84.6)</td></tr><tr><td align="left" valign="top">Mean change in HbA<sub>1c</sub>, % (95% CI; <italic>P</italic> value)</td><td align="left" valign="top">&#x2212;1.2 (95% CI &#x2212;1.43 to &#x2212;0.93; <italic>P</italic>&#x003C;.001)</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><p><sup>a</sup>HbA<sub>1c</sub>: glycated hemoglobin.</p></fn></table-wrap-foot></table-wrap><p>Overall, 65.4% (68/104) of participants achieved the predefined HbA<sub>1c</sub> reduction threshold of &#x2265;0.6%. Additionally, 84.6% (n=88) of participants demonstrated an overall reduction in HbA<sub>1c</sub> following the intervention. A total of 1.9% (n=2) of participants had no change, and 13.5% (n=14) of participants had an increase in HbA<sub>1c</sub> following the intervention.</p><p>Individual changes in HbA<sub>1c</sub> following the intervention are illustrated in <xref ref-type="fig" rid="figure2">Figure 2</xref>, demonstrating that most participants experienced reductions in HbA<sub>1c</sub> levels after the 16-week intervention.</p></sec><sec id="s3-3"><title>Secondary Outcomes</title><sec id="s3-3-1"><title>Metabolic Outcomes</title><p>Significant improvements were observed in FBG, total cholesterol, and triglycerides. <xref ref-type="table" rid="table3">Table 3</xref> summarizes changes in metabolic outcomes following the intervention.</p><fig position="float" id="figure2"><label>Figure 2.</label><caption><p>Individual changes in glycated hemoglobin (HbA<sub>1c</sub>) levels following the 16-week intervention (N=104). Negative values indicate a reduction in HbA<sub>1c</sub> from baseline, while positive values indicate increases in HbA<sub>1c</sub>.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="formative_v10i1e94551_fig02.png"/></fig><table-wrap id="t3" position="float"><label>Table 3.</label><caption><p>Changes in metabolic outcomes following the 16-week intervention.</p></caption><table id="table3" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Outcomes</td><td align="left" valign="bottom">n</td><td align="left" valign="bottom">Baseline, mean (SD)</td><td align="left" valign="bottom">End point, mean (SD)</td><td align="left" valign="bottom">Change, mean (SD)</td><td align="left" valign="bottom">95% CI for change</td><td align="left" valign="bottom"><italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" valign="top">FBG<sup><xref ref-type="table-fn" rid="table3fn1">a</xref></sup>, mmol/L</td><td align="left" valign="top">103<sup><xref ref-type="table-fn" rid="table3fn2">b</xref></sup></td><td align="left" valign="top">9.3 (2.9)</td><td align="left" valign="top">7.6 (2.2)</td><td align="left" valign="top">&#x2212;1.7 (2.8)</td><td align="left" valign="top">&#x2212;2.3 to &#x2212;1.2</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Total cholesterol, mmol/L</td><td align="left" valign="top">104</td><td align="left" valign="top">4.9 (1.0)</td><td align="left" valign="top">4.6 (0.8)</td><td align="left" valign="top">&#x2212;0.3 (1.0)</td><td align="left" valign="top">&#x2212;0.6 to &#x2212;0.2</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">HDL-C<sup><xref ref-type="table-fn" rid="table3fn3">c</xref></sup>, mmol/L</td><td align="left" valign="top">102<sup><xref ref-type="table-fn" rid="table3fn2">b</xref></sup></td><td align="left" valign="top">1.2 (0.2)</td><td align="left" valign="top">1.1 (0.2)</td><td align="left" valign="top">&#x2212;0.02 (0.14)</td><td align="left" valign="top">&#x2212;0.1 to 0.00</td><td align="left" valign="top">.10</td></tr><tr><td align="left" valign="top">LDL-C<sup><xref ref-type="table-fn" rid="table3fn4">d</xref></sup>, mmol/L</td><td align="left" valign="top">102<sup><xref ref-type="table-fn" rid="table3fn2">b</xref></sup></td><td align="left" valign="top">2.9 (0.8)</td><td align="left" valign="top">2.7 (0.7)</td><td align="left" valign="top">&#x2212;0.2 (0.8)</td><td align="left" valign="top">&#x2212;0.3 to 0.0</td><td align="left" valign="top">.14</td></tr><tr><td align="left" valign="top">Triglycerides, mmol/L</td><td align="left" valign="top">104</td><td align="left" valign="top">1.9 (1.7)</td><td align="left" valign="top">1.5 (0.8)</td><td align="left" valign="top">&#x2212;0.5 (1.3)</td><td align="left" valign="top">&#x2212;0.7 to &#x2212;0.2</td><td align="left" valign="top">&#x003C;.001</td></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><p><sup>a</sup>FBG: fasting blood glucose.</p></fn><fn id="table3fn2"><p><sup>b</sup>One participant did not complete the end point FBG assessment. LDL-C and HDL-C values were unavailable for 2 participants because values could not be calculated due to elevated triglyceride levels.</p></fn><fn id="table3fn3"><p><sup>c</sup>HDL-C: high-density lipoprotein cholesterol.</p></fn><fn id="table3fn4"><p><sup>d</sup>LDL-C: low-density lipoprotein cholesterol.</p></fn></table-wrap-foot></table-wrap><p>Among 103 participants with complete FBG data, mean FBG decreased significantly from 9.3 (SD 2.9) mmol/L at baseline to 7.6 (SD 2.2) mmol/L at week 16, representing a mean reduction of 1.7 mmol/L (95% CI &#x2212;2.26 to &#x2212;1.17; <italic>P</italic>&#x003C;.001).</p><p>Lipid profile analyses demonstrated significant improvements in total cholesterol and triglyceride levels. Mean total cholesterol decreased from 4.9 (SD 1.0) mmol/L to 4.6 (SD 0.8) mmol/L, representing a mean reduction of 0.3 mmol/L (95% CI &#x2212;0.55 to &#x2212;0.17; <italic>P</italic>&#x003C;.001). Mean triglyceride levels decreased from 1.9 (SD 1.7) mmol/L to 1.5 (SD 0.8) mmol/L, corresponding to a mean reduction of 0.5 mmol/L (95% CI &#x2212;0.69 to &#x2212;0.20; <italic>P</italic>&#x003C;.001).</p><p>Reductions in LDL-C and HDL-C were also observed; however, these changes did not meet the predefined threshold for statistical significance.</p></sec><sec id="s3-3-2"><title>Anthropometric Outcomes</title><p>Significant improvements in anthropometric measures were observed following the intervention (<xref ref-type="table" rid="table4">Table 4</xref>).</p><table-wrap id="t4" position="float"><label>Table 4.</label><caption><p>Changes in anthropometric outcomes following the 16-week intervention.</p></caption><table id="table4" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Outcomes</td><td align="left" valign="bottom">n</td><td align="left" valign="bottom">Baseline, mean (SD)</td><td align="left" valign="bottom">End point, mean (SD)</td><td align="left" valign="bottom">Change, mean (SD)</td><td align="left" valign="bottom">95% CI for change</td><td align="left" valign="bottom"><italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" valign="top">BMI, kg/m<sup>2</sup></td><td align="left" valign="top">103</td><td align="left" valign="top">33.0 (6.6)</td><td align="left" valign="top">32.6 (6.8)</td><td align="left" valign="top">&#x2212;0.4 (1.0)</td><td align="left" valign="top">&#x2212;0.6 to &#x2212;0.2</td><td align="left" valign="top">&#x003C;.001</td></tr><tr><td align="left" valign="top">Waist circumference, cm</td><td align="left" valign="top">103</td><td align="left" valign="top">105.4 (14.2)</td><td align="left" valign="top">103.5 (14.9)</td><td align="left" valign="top">&#x2212;1.9 (5.2)</td><td align="left" valign="top">&#x2212;2.9 to &#x2212;0.9</td><td align="left" valign="top">&#x003C;.001</td></tr></tbody></table></table-wrap><p>Mean BMI decreased from 33.0 (SD 6.6) kg/m&#x00B2; to 32.6 (SD 6.8) kg/m&#x00B2;, representing a mean reduction of 0.4 kg/m&#x00B2; (95% CI &#x2212;0.60 to &#x2212;0.22; <italic>P</italic>&#x003C;.001). Mean waist circumference decreased from 105.38 (SD 14.17) cm to 103.49 (SD 14.91) cm, corresponding to a mean reduction of 1.89 cm (95% CI &#x2212;2.90 to &#x2212;0.89; <italic>P</italic>&#x003C;.001). In sex-stratified analyses, male participants demonstrated a reduction in waist circumference from 108.7 (SD 14.4) cm to 106.8 (SD 14.1) cm, corresponding to a mean reduction of 1.9 cm (95% CI &#x2212;2.93 to &#x2212;0.94; <italic>P</italic>&#x003C;.001). Female participants demonstrated a reduction from 104.7 (SD 14.1) cm to 102.8 (SD 15.3) cm, corresponding to a mean reduction of 1.9 cm (95% CI &#x2212;3.59 to &#x2212;0.13; <italic>P</italic>=.036), although this did not meet the predefined study significance threshold of <italic>P</italic>&#x003C;.001.</p><p>Sex-stratified changes in BMI and waist circumference are summarized in <xref ref-type="supplementary-material" rid="app3">Multimedia Appendix 3</xref>.</p></sec><sec id="s3-3-3"><title>QoL Outcomes</title><p>Among 101 participants with complete QoL data, mean EQ-VAS scores improved significantly from 79.4 (SD 16.6) at baseline to 86.1 (SD 12.2) after the intervention. This represented a mean increase of 6.7 points (95% CI 3.9 to 9.6; <italic>P</italic>&#x003C;.001).</p><p>Improvements were additionally observed across all EQ-5D-5L domains following the intervention, with higher proportions of participants reporting &#x201C;no problems&#x201D; at end point assessment compared with baseline assessment (<xref ref-type="table" rid="table5">Table 5</xref>). The largest improvements were observed in the pain/discomfort domain, from 65.3% (66/101) of participants at baseline to 82.1% (83/101) of participants at end point, and in the anxiety/depression domain, from 67.3% (68/101) of participants at baseline to 80.2% (81) of participants at end point. Under the predefined study statistical threshold of <italic>P</italic>&#x003C;.001, none of the EQ-5D-5L domain improvements reached statistical significance, although the pain/discomfort domain showed the lowest <italic>P</italic> value (<italic>P</italic>=.002).</p><table-wrap id="t5" position="float"><label>Table 5.</label><caption><p>EQ-5D-5L domain outcomes at baseline and end point.</p></caption><table id="table5" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">EQ-5D-5L dimension</td><td align="left" valign="bottom">No problems at baseline, n (%)</td><td align="left" valign="bottom">No problems at end point, n (%)</td><td align="left" valign="bottom"><italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" valign="top">Mobility</td><td align="left" valign="top">90 (89.1)</td><td align="left" valign="top">98 (97)</td><td align="left" valign="top">.02</td></tr><tr><td align="left" valign="top">Self-care</td><td align="left" valign="top">99 (98)</td><td align="left" valign="top">100 (99)</td><td align="left" valign="top">&#x003E;.99</td></tr><tr><td align="left" valign="top">Usual activities</td><td align="left" valign="top">87 (86.1)</td><td align="left" valign="top">95 (94.1)</td><td align="left" valign="top">.02</td></tr><tr><td align="left" valign="top">Pain/discomfort</td><td align="left" valign="top">66 (65.3)</td><td align="left" valign="top">83 (82.1)</td><td align="left" valign="top">.002</td></tr><tr><td align="left" valign="top">Anxiety/depression</td><td align="left" valign="top">68 (67.3)</td><td align="left" valign="top">81 (80.2)</td><td align="left" valign="top">.04</td></tr></tbody></table></table-wrap></sec><sec id="s3-3-4"><title>Engagement and Feasibility Outcomes</title><p>Participant engagement throughout the intervention remained high. Of the 122 participants enrolled, 108 (88.5%) participants completed the 16-week intervention, while 10 (8.2%) participants withdrew from the study and 4 (3.3%) participants did not attend any health coach VCs.</p><p>Engagement was additionally supported through structured reminder workflows, including weekly WhatsApp reminders for diary card submission, consultation reminders prior to scheduled appointments, and ongoing asynchronous communication with health coaches throughout the intervention period.</p><p>Among participants who completed the intervention, 64.8% (70/108) of participants attended all 7 scheduled VCs, while 75.9% (82/108) of participants attended at least 5 VCs throughout the intervention period. No intervention-related serious adverse events were reported throughout the study (<xref ref-type="table" rid="table6">Table 6</xref>).</p><table-wrap id="t6" position="float"><label>Table 6.</label><caption><p>Engagement and feasibility outcomes (N=122).<sup><xref ref-type="table-fn" rid="table6fn1">a</xref></sup></p></caption><table id="table6" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Category</td><td align="left" valign="bottom">Result, n (%)</td></tr></thead><tbody><tr><td align="left" valign="top">Participants completing intervention</td><td align="left" valign="top">108 (88.5)</td></tr><tr><td align="left" valign="top">Withdrawals</td><td align="left" valign="top">10 (8.2)</td></tr><tr><td align="left" valign="top">Did not attend any VC<sup><xref ref-type="table-fn" rid="table6fn2">b</xref></sup></td><td align="left" valign="top">4 (3.3)</td></tr><tr><td align="left" valign="top">Attended all 7 VCs</td><td align="left" valign="top">70 (64.8)</td></tr><tr><td align="left" valign="top">Attended &#x2265;5 VCs</td><td align="left" valign="top">82 (75.9)</td></tr></tbody></table><table-wrap-foot><fn id="table6fn1"><p><sup>a</sup>Percentages for participants completing intervention, withdrawals, and participants who did not attend any video consultations were calculated using the total enrolled population as denominator (N=122). Percentages for attendance at video consultations were calculated using participants who completed the intervention as the denominator (N=108).</p></fn><fn id="table6fn2"><p><sup>b</sup>VC: video consultation.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3-4"><title>Participant Feedback and Intervention Acceptability</title><p>Postintervention feedback from 91.7% (99/108) of participants who completed the intervention was analyzed (<xref ref-type="table" rid="table7">Table 7</xref>). The feedback questionnaire assessed study satisfaction, intervention duration, achievement of SMART goals, usefulness of learning materials, diabetes self-management, and experiences with health coaches. Participant feedback on study satisfaction and intervention duration was assessed using a 5-point Likert scale (1=extremely dissatisfied, 2=dissatisfied, 3=neutral satisfaction, 4=satisfied, and 5=extremely satisfied).</p><table-wrap id="t7" position="float"><label>Table 7.</label><caption><p>Answers reported by participants in the participant feedback and intervention acceptability survey (N=99).</p></caption><table id="table7" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Category</td><td align="left" valign="bottom">Participants, n (%)</td></tr></thead><tbody><tr><td align="left" valign="top">Satisfied/extremely satisfied with intervention</td><td align="left" valign="top">86 (86.9)</td></tr><tr><td align="left" valign="top">Intervention helped achieve SMART<sup><xref ref-type="table-fn" rid="table7fn1">a</xref></sup> goals</td><td align="left" valign="top">83 (83.8)</td></tr><tr><td align="left" valign="top">Dietary recommendations useful</td><td align="left" valign="top">84 (84.8)</td></tr><tr><td align="left" valign="top">Online consultations useful</td><td align="left" valign="top">82 (82.8)</td></tr><tr><td align="left" valign="top">Improved understanding of diabetes self-management</td><td align="left" valign="top">86 (86.9)</td></tr><tr><td align="left" valign="top">Improved eating habits</td><td align="left" valign="top">85 (85.9)</td></tr><tr><td align="left" valign="top">Increased confidence in blood glucose self-monitoring</td><td align="left" valign="top">77 (77.8)</td></tr><tr><td align="left" valign="top">Adoption of a more physically active lifestyle</td><td align="left" valign="top">69 (69.7)</td></tr><tr><td align="left" valign="top">Health coach advice very helpful</td><td align="left" valign="top">92 (92.9)</td></tr></tbody></table><table-wrap-foot><fn id="table7fn1"><p><sup>a</sup>SMART: Specific, Measurable, Achievable, Relevant, and Time-bound.</p></fn></table-wrap-foot></table-wrap><p>Overall satisfaction with the intervention was high, with 86.9% (86/99) of participants reporting that they were satisfied or extremely satisfied with the study. Most participants (n=83, 83.8%) reported that the intervention helped them achieve SMART goals related to diabetes self-management. Dietary recommendations (n=84, 84.8%) and online consultations with health coaches (n=82, 82.8%) were identified as the most useful intervention components.</p><p>Participants additionally reported improvements in multiple self-management behaviors, including improved understanding of diabetes self-management (n=86, 86.9%), improved eating habits (n=85, 85.9%), increased confidence in self-monitoring blood glucose levels (n=77, 77.8%), and adoption of a more physically active lifestyle (n=69, 69.7%).</p><p>Most participants (n=92, 92.9%) also reported that advice provided by health coaches was very helpful in supporting diabetes self-management.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>This pilot trial provides preliminary evidence supporting the feasibility and potential effectiveness of a hybrid digital health intervention for individuals with T2DM in Brunei Darussalam. Participation in the 16-week intervention was associated with significant improvements in glycemic control, anthropometric measures, lipid parameters, and health-related QoL. Participants additionally demonstrated high engagement, intervention completion, and overall satisfaction with the study.</p><p>The intervention was associated with a clinically meaningful reduction in HbA<sub>1c</sub>, with a mean reduction of 1.2 percentage points. Significant improvements were also observed in FBG, BMI, waist circumference, total cholesterol, triglyceride levels, and EQ-VAS scores. These findings suggest that comprehensive digital interventions integrating structured education, personalized coaching, and self-monitoring support may improve multiple aspects of diabetes management.</p></sec><sec id="s4-2"><title>Comparison With Prior Work</title><p>The improvements in glycemic control observed in this study compare favorably with existing literature evaluating digital interventions for T2DM management. A systematic review by Stevens et al [<xref ref-type="bibr" rid="ref10">10</xref>] reported reductions in HbA<sub>1c</sub> in 19 out of 20 intervention groups, with an average decrease of 0.9%. Similarly, Eberle et al [<xref ref-type="bibr" rid="ref11">11</xref>] reported that disease-specific mHealth interventions were associated with improvements in glycemic outcomes, with an average HbA<sub>1c</sub> reduction of 1.1% among individuals with T2DM.</p><p>A more recent systematic review and meta-analysis by Kerr et al [<xref ref-type="bibr" rid="ref16">16</xref>] additionally demonstrated that digital interventions incorporating personalized coaching, structured self-monitoring, and higher-intensity engagement strategies were associated with greater glycemic improvements and improved self-management behaviors. The present findings are consistent with this literature, particularly given the intervention&#x2019;s incorporation of regular health coach interaction, asynchronous communication, structured educational support, and ongoing self-monitoring activities.</p><p>Several components of the intervention may have contributed to the observed outcomes. The study incorporated personalized coaching, SMART goal setting, weekly education reinforcement, and flexible communication between participants and health coaches. Previous evidence suggests that asynchronous communication may facilitate sustained patient engagement by allowing flexible interactions without the scheduling limitations of conventional in-person consultations [<xref ref-type="bibr" rid="ref16">16</xref>]. Personalized coaching and goal setting may additionally support behavior change by promoting self-efficacy, accountability, and adherence to dietary and physical activity recommendations.</p><p>The intervention was additionally associated with significant improvements in FBG, BMI, waist circumference, total cholesterol, and triglyceride levels. The reductions observed in triglycerides may reflect the strong dietary and lifestyle modification components incorporated within the intervention, including structured nutritional guidance, dietary self-monitoring, and continuous behavioral reinforcement from health coaches. Previous reviews evaluating digital lifestyle interventions have similarly reported improvements in metabolic and anthropometric outcomes following interventions incorporating dietary counseling and self-management support [<xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref18">18</xref>].</p><p>Although trends toward improvement were observed in HDL-C and LDL-C levels, these changes did not reach statistical significance. This may particularly reflect the pragmatic nature of the intervention, which emphasized general lifestyle modification and diabetes self-management support rather than rigidly structured exercise prescription. Physical activity recommendations were incorporated as part of general lifestyle counseling and health coaching, but no formal exercise prescription or supervised exercise program was implemented. Consequently, the intervention may not have provided sufficient exercise stimulus to elicit substantial changes in HDL-C and LDL-C levels. Future studies incorporating longer intervention periods and more intensive, structured exercise components may be needed to demonstrate significant improvements in these lipid outcomes.</p><p>The intervention was also associated with improvements in health-related QoL outcomes. Individuals living with T2DM frequently experience reduced QoL, impaired psychological well-being, and poorer social function, which may negatively affect long-term self-management and adherence to treatment recommendations [<xref ref-type="bibr" rid="ref19">19</xref>]. Previous studies have demonstrated that behavioral and lifestyle interventions may improve both diabetes-related outcomes and QoL measures among individuals with T2DM [<xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref>].</p><p>In this study, participants demonstrated improvements across all EQ-5D-5L domains, with the largest improvements observed in the pain or discomfort and anxiety or depression domains. The significant improvement in EQ-VAS scores further supports participants&#x2019; perceived improvements in overall health status following the intervention.</p></sec><sec id="s4-3"><title>Feasibility and Acceptability</title><p>The findings additionally support the feasibility and acceptability of the intervention within a real-world national digital health setting. The intervention achieved a high completion rate of 88.5% (108/122), with most participants attending at least 5 scheduled VCs throughout the intervention period. High levels of participant satisfaction, perceived usefulness of dietary guidance, and positive experiences with health coaches were observed.</p><p>Participant engagement was supported through asynchronous communication workflows, weekly reminder systems, consultation reminders, and continuous access to health coaches throughout the intervention. These findings are important because many digital health studies primarily focus on glycemic outcomes while providing limited evaluation of participant engagement, acceptability, and perceived usefulness.</p><p>The high retention and engagement observed in this study suggest that integrating personalized coaching, structured reminders, and flexible digital communication platforms may support sustained participation in diabetes self-management interventions within routine care settings. However, despite generally positive engagement outcomes, adoption of more physically active lifestyles was comparatively lower than improvements in dietary behaviors, and self-management behaviors and understanding. This may reflect the challenges associated with sustaining exercise behavior change in real-world digital interventions. While participants received general physical activity guidance and encouragement throughout the intervention, the study did not incorporate structured exercise prescription, supervised exercise sessions, or individualized exercise training regimens. Future interventions may benefit from incorporating more structured exercise components to support long-term physical activity adherence and optimize cardiometabolic outcomes.</p><p>A major strength of this intervention was its integration within Brunei Darussalam&#x2019;s existing national digital health ecosystem through the BruHealth platform. This approach enabled structured remote support while reducing reliance on frequent in-person consultations. Such hybrid digital care models may be particularly valuable in settings with constrained health care resources and increasing chronic disease burden.</p></sec><sec id="s4-4"><title>Strengths and Limitations</title><p>This study has several strengths. The intervention combined digital self-management support with personalized coaching and offline clinical support, reflecting a pragmatic real-world implementation model. The study additionally evaluated not only clinical outcomes but also QoL, engagement, feasibility, and participant acceptability outcomes, providing a broader assessment of intervention effectiveness.</p><p>Several limitations should also be considered. First, the single-arm, nonrandomized design limits causal inference and precludes direct comparison with standard care. Second, the relatively short intervention duration limits evaluation of the long-term sustainability of observed improvements. Third, self-reported dietary intake, physical activity, and weight records may be subject to recall and reporting bias. Finally, exclusion of individuals receiving insulin therapy or with advanced diabetes-related complications may limit generalizability to the broader T2DM population.</p></sec><sec id="s4-5"><title>Implications for Practice and Future Research</title><p>The findings from this pilot study support the potential role of hybrid digital interventions in improving diabetes outcomes within national health systems. Integration of digital coaching and remote self-management support within existing health infrastructure may help optimize resource utilization while expanding access to structured diabetes care.</p><p>Future studies should include randomized controlled designs with longer follow-up periods to evaluate long-term sustainability, cost-effectiveness, and scalability of digital diabetes interventions. Further evaluation of patient engagement patterns and intervention adherence may additionally help identify the components most strongly associated with clinical improvement.</p></sec><sec id="s4-6"><title>Conclusions</title><p>This pilot study provides preliminary evidence that a hybrid digital health intervention integrating personalized coaching, structured education, and remote self-management may improve glycemic control, metabolic outcomes, health-related QoL, and patient engagement among individuals with T2DM in Brunei Darussalam.</p><p>Integration within the BruHealth platform demonstrates the potential scalability of digital diabetes management strategies within routine care settings. Further large-scale controlled studies with longer follow-up durations are warranted to evaluate long-term sustainability, implementation outcomes, and cost-effectiveness.</p></sec></sec></body><back><ack><p>The authors would like to acknowledge the contributions of the EVYD team for their support in research coordination, data extraction, and application development. This study was conducted as part of a collaboration between the Ministry of Health, Brunei Darussalam, and EVYD Technology Sdn Bhd. The generative artificial intelligence tool ChatGPT (GPT-5.5; OpenAI) was used to assist with language refinement, manuscript structuring, and editorial drafting support. All scientific content, statistical analyses, interpretation of findings, and final manuscript revisions were reviewed and verified by the authors, who take full responsibility for the integrity and accuracy of the work.</p></ack><notes><sec><title>Funding</title><p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec><sec><title>Data Availability</title><p>The datasets analyzed during the current study were provided by the Ministry of Health, Brunei Darussalam, and were used solely for the purposes of this research and prototype development. Due to data governance, privacy, and institutional restrictions, the datasets are not publicly available. Reasonable requests for access may be considered subject to approval by the Ministry of Health, Brunei Darussalam, and relevant institutional requirements.</p></sec></notes><fn-group><fn fn-type="con"><p>AMLY, CPL, CKY, MM, and LHS were the principal investigators of the study. CHN and CY contributed as dietitians. CSY, YL, and AY contributed as health coaches. CSY and SM performed the data analysis. AMLY, CPL, CKY, and MM led the preparation of the manuscript, and SM was responsible for the manuscript submission. All authors reviewed and approved the final manuscript.</p></fn><fn fn-type="conflict"><p>HNC, SM, SYC, YLHW, AY, YC, and HSL are employed by EVYD Technology. EVYD Technology served as the technology partner and research collaborator in this study and was involved in the development of the BruHealth app. The authors declare no other conflicts of interest.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">DEsireD</term><def><p>Development and Exploration of Effectiveness and Feasibility of Digital Intervention for Type 2 Diabetes Mellitus</p></def></def-item><def-item><term id="abb2">DTx</term><def><p>digital therapeutics</p></def></def-item><def-item><term id="abb3">EQ-VAS</term><def><p>EuroQol Visual Analog Scale</p></def></def-item><def-item><term id="abb4">FBG</term><def><p>fasting blood glucose</p></def></def-item><def-item><term id="abb5">HbA<sub>1c</sub></term><def><p>glycated hemoglobin</p></def></def-item><def-item><term id="abb6">HDL-C</term><def><p>high-density lipoprotein cholesterol</p></def></def-item><def-item><term id="abb7">LDL-C</term><def><p>low-density lipoprotein cholesterol</p></def></def-item><def-item><term id="abb8">mHealth</term><def><p>mobile health</p></def></def-item><def-item><term id="abb9">QoL</term><def><p>quality of life</p></def></def-item><def-item><term id="abb10">SMART</term><def><p>Specific, Measurable, Achievable, Relevant, and Time-bound</p></def></def-item><def-item><term id="abb11">T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item><def-item><term id="abb12">VC</term><def><p>video consultation</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Ley</surname><given-names>SH</given-names> </name><name name-style="western"><surname>Hu</surname><given-names>FB</given-names> </name></person-group><article-title>Global aetiology and epidemiology of type 2 diabetes mellitus and its complications</article-title><source>Nat Rev Endocrinol</source><year>2018</year><month>02</month><volume>14</volume><issue>2</issue><fpage>88</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2017.151</pub-id><pub-id pub-id-type="medline">29219149</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H</given-names> </name><name name-style="western"><surname>Saeedi</surname><given-names>P</given-names> </name><name name-style="western"><surname>Karuranga</surname><given-names>S</given-names> </name><etal/></person-group><article-title>IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045</article-title><source>Diabetes Res Clin Pract</source><year>2022</year><month>01</month><volume>183</volume><fpage>109119</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2021.109119</pub-id><pub-id pub-id-type="medline">34879977</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knowler</surname><given-names>WC</given-names> </name><name name-style="western"><surname>Barrett-Connor</surname><given-names>E</given-names> </name><name name-style="western"><surname>Fowler</surname><given-names>SE</given-names> </name><etal/></person-group><article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</article-title><source>N Engl J Med</source><year>2002</year><month>02</month><day>7</day><volume>346</volume><issue>6</issue><fpage>393</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa012512</pub-id><pub-id pub-id-type="medline">11832527</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lean</surname><given-names>ME</given-names> </name><name name-style="western"><surname>Leslie</surname><given-names>WS</given-names> </name><name name-style="western"><surname>Barnes</surname><given-names>AC</given-names> </name><etal/></person-group><article-title>Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial</article-title><source>Lancet</source><year>2018</year><month>02</month><volume>391</volume><issue>10120</issue><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33102-1</pub-id><pub-id pub-id-type="medline">29221645</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glasgow</surname><given-names>RE</given-names> </name><name name-style="western"><surname>Peeples</surname><given-names>M</given-names> </name><name name-style="western"><surname>Skovlund</surname><given-names>SE</given-names> </name></person-group><article-title>Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures</article-title><source>Diabetes Care</source><year>2008</year><month>05</month><volume>31</volume><issue>5</issue><fpage>1046</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.2337/dc07-1845</pub-id><pub-id pub-id-type="medline">18445728</pub-id></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dang</surname><given-names>A</given-names> </name><name name-style="western"><surname>Arora</surname><given-names>D</given-names> </name><name name-style="western"><surname>Rane</surname><given-names>P</given-names> </name></person-group><article-title>Role of digital therapeutics and the changing future of healthcare</article-title><source>J Family Med Prim Care</source><year>2020</year><month>05</month><volume>9</volume><issue>5</issue><fpage>2207</fpage><lpage>2213</lpage><pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_105_20</pub-id><pub-id pub-id-type="medline">32754475</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinn</surname><given-names>CC</given-names> </name><name name-style="western"><surname>Clough</surname><given-names>SS</given-names> </name><name name-style="western"><surname>Minor</surname><given-names>JM</given-names> </name><name name-style="western"><surname>Lender</surname><given-names>D</given-names> </name><name name-style="western"><surname>Okafor</surname><given-names>MC</given-names> </name><name name-style="western"><surname>Gruber-Baldini</surname><given-names>A</given-names> </name></person-group><article-title>WellDoc mobile diabetes management randomized controlled trial: change in clinical and behavioral outcomes and patient and physician satisfaction</article-title><source>Diabetes Technol Ther</source><year>2008</year><month>06</month><volume>10</volume><issue>3</issue><fpage>160</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1089/dia.2008.0283</pub-id><pub-id pub-id-type="medline">18473689</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>DA</given-names> </name><name name-style="western"><surname>Gee</surname><given-names>PM</given-names> </name><name name-style="western"><surname>Fatkin</surname><given-names>KJ</given-names> </name><name name-style="western"><surname>Peeples</surname><given-names>M</given-names> </name></person-group><article-title>A systematic review of reviews evaluating technology-enabled diabetes self-management education and support</article-title><source>J Diabetes Sci Technol</source><year>2017</year><month>09</month><volume>11</volume><issue>5</issue><fpage>1015</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1177/1932296817713506</pub-id><pub-id pub-id-type="medline">28560898</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonoto</surname><given-names>BC</given-names> </name><name name-style="western"><surname>de Ara&#x00FA;jo</surname><given-names>VE</given-names> </name><name name-style="western"><surname>God&#x00F3;i</surname><given-names>IP</given-names> </name><etal/></person-group><article-title>Efficacy of mobile apps to support the care of patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials</article-title><source>JMIR Mhealth Uhealth</source><year>2017</year><month>03</month><day>1</day><volume>5</volume><issue>3</issue><fpage>e4</fpage><pub-id pub-id-type="doi">10.2196/mhealth.6309</pub-id><pub-id pub-id-type="medline">28249834</pub-id></nlm-citation></ref><ref id="ref10"><label>10</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>S</given-names> </name><name name-style="western"><surname>Gallagher</surname><given-names>S</given-names> </name><name name-style="western"><surname>Andrews</surname><given-names>T</given-names> </name><name name-style="western"><surname>Ashall-Payne</surname><given-names>L</given-names> </name><name name-style="western"><surname>Humphreys</surname><given-names>L</given-names> </name><name name-style="western"><surname>Leigh</surname><given-names>S</given-names> </name></person-group><article-title>The effectiveness of digital health technologies for patients with diabetes mellitus: a systematic review</article-title><source>Front Clin Diabetes Healthc</source><year>2022</year><volume>3</volume><fpage>936752</fpage><pub-id pub-id-type="doi">10.3389/fcdhc.2022.936752</pub-id><pub-id pub-id-type="medline">36992773</pub-id></nlm-citation></ref><ref id="ref11"><label>11</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eberle</surname><given-names>C</given-names> </name><name name-style="western"><surname>L&#x00F6;hnert</surname><given-names>M</given-names> </name><name name-style="western"><surname>Stichling</surname><given-names>S</given-names> </name></person-group><article-title>Effectiveness of disease-specific mhealth apps in patients with diabetes mellitus: scoping review</article-title><source>JMIR Mhealth Uhealth</source><year>2021</year><month>02</month><day>15</day><volume>9</volume><issue>2</issue><fpage>e23477</fpage><pub-id pub-id-type="doi">10.2196/23477</pub-id><pub-id pub-id-type="medline">33587045</pub-id></nlm-citation></ref><ref id="ref12"><label>12</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Lin</surname><given-names>W</given-names> </name><name name-style="western"><surname>Wen</surname><given-names>J</given-names> </name><name name-style="western"><surname>Chen</surname><given-names>G</given-names> </name></person-group><article-title>Impact and efficacy of mobile health intervention in the management of diabetes and hypertension: a systematic review and meta-analysis</article-title><source>BMJ Open Diabetes Res Care</source><year>2020</year><month>09</month><volume>8</volume><issue>1</issue><fpage>e001225</fpage><pub-id pub-id-type="doi">10.1136/bmjdrc-2020-001225</pub-id><pub-id pub-id-type="medline">32988849</pub-id></nlm-citation></ref><ref id="ref13"><label>13</label><nlm-citation citation-type="web"><article-title>Population, total - Brunei Darussalam</article-title><source>World Bank Group</source><year>2023</year><access-date>2026-07-03</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://data.worldbank.org/indicator/SP.POP.TOTL?locations=BN">https://data.worldbank.org/indicator/SP.POP.TOTL?locations=BN</ext-link></comment></nlm-citation></ref><ref id="ref14"><label>14</label><nlm-citation citation-type="report"><article-title>Brunei Darussalam STEPS survey 2022/23 fact sheet</article-title><year>2025</year><access-date>2025-02-01</access-date><publisher-name>Ministry of Health Brunei Darussalam</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="https://moh.gov.bn/wp-content/uploads/2025/11/BRN-2023_Factsheet_18-Nov-24_15-36-39-FINAL_140425.pdf">https://moh.gov.bn/wp-content/uploads/2025/11/BRN-2023_Factsheet_18-Nov-24_15-36-39-FINAL_140425.pdf</ext-link></comment></nlm-citation></ref><ref id="ref15"><label>15</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>HN</given-names> </name><name name-style="western"><surname>Lim</surname><given-names>HS</given-names> </name><name name-style="western"><surname>Chong</surname><given-names>PL</given-names> </name><etal/></person-group><article-title>Development and exploration of the effectiveness and feasibility of a digital intervention for type 2 diabetes mellitus (DEsireD): protocol for a clinical nonrandomized pilot trial in Brunei Darussalam</article-title><source>JMIR Res Protoc</source><year>2022</year><month>12</month><day>7</day><volume>11</volume><issue>12</issue><fpage>e43208</fpage><pub-id pub-id-type="doi">10.2196/43208</pub-id><pub-id pub-id-type="medline">36477014</pub-id></nlm-citation></ref><ref id="ref16"><label>16</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>D</given-names> </name><name name-style="western"><surname>Ahn</surname><given-names>D</given-names> </name><name name-style="western"><surname>Waki</surname><given-names>K</given-names> </name><name name-style="western"><surname>Wang</surname><given-names>J</given-names> </name><name name-style="western"><surname>Breznen</surname><given-names>B</given-names> </name><name name-style="western"><surname>Klonoff</surname><given-names>DC</given-names> </name></person-group><article-title>Digital interventions for self-management of type 2 diabetes mellitus: systematic literature review and meta-analysis</article-title><source>J Med Internet Res</source><year>2024</year><month>07</month><day>22</day><volume>26</volume><fpage>e55757</fpage><pub-id pub-id-type="doi">10.2196/55757</pub-id><pub-id pub-id-type="medline">39037772</pub-id></nlm-citation></ref><ref id="ref17"><label>17</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veazie</surname><given-names>S</given-names> </name><name name-style="western"><surname>Winchell</surname><given-names>K</given-names> </name><name name-style="western"><surname>Gilbert</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Rapid evidence review of mobile applications for self-management of diabetes</article-title><source>J Gen Intern Med</source><year>2018</year><month>07</month><volume>33</volume><issue>7</issue><fpage>1167</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1007/s11606-018-4410-1</pub-id><pub-id pub-id-type="medline">29740786</pub-id></nlm-citation></ref><ref id="ref18"><label>18</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names> </name><name name-style="western"><surname>Li</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Prognostic effectiveness of interactive vs. non-interactive mobile app interventions in type 2 diabetes: a systematic review and meta-analysis</article-title><source>Arch Public Health</source><year>2024</year><month>11</month><day>22</day><volume>82</volume><issue>1</issue><fpage>221</fpage><pub-id pub-id-type="doi">10.1186/s13690-024-01450-x</pub-id><pub-id pub-id-type="medline">39578910</pub-id></nlm-citation></ref><ref id="ref19"><label>19</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>X</given-names> </name><name name-style="western"><surname>Astell-Burt</surname><given-names>T</given-names> </name></person-group><article-title>Impact of a type 2 diabetes diagnosis on mental health, quality of life, and social contacts: a longitudinal study</article-title><source>BMJ Open Diabetes Res Care</source><year>2017</year><volume>5</volume><issue>1</issue><fpage>e000198</fpage><pub-id pub-id-type="doi">10.1136/bmjdrc-2016-000198</pub-id><pub-id pub-id-type="medline">28243446</pub-id></nlm-citation></ref><ref id="ref20"><label>20</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>BX</given-names> </name><name name-style="western"><surname>Nguyen</surname><given-names>LH</given-names> </name><name name-style="western"><surname>Pham</surname><given-names>NM</given-names> </name><etal/></person-group><article-title>Global mapping of interventions to improve quality of life of people with diabetes in 1990-2018</article-title><source>Int J Environ Res Public Health</source><year>2020</year><month>03</month><day>2</day><volume>17</volume><issue>5</issue><fpage>1597</fpage><pub-id pub-id-type="doi">10.3390/ijerph17051597</pub-id><pub-id pub-id-type="medline">32121642</pub-id></nlm-citation></ref><ref id="ref21"><label>21</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names> </name><name name-style="western"><surname>Norris</surname><given-names>SL</given-names> </name><name name-style="western"><surname>Chowdhury</surname><given-names>FM</given-names> </name><name name-style="western"><surname>Gregg</surname><given-names>EW</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names> </name></person-group><article-title>The effects of interventions on health-related quality of life among persons with diabetes: a systematic review</article-title><source>Med Care</source><year>2007</year><month>09</month><volume>45</volume><issue>9</issue><fpage>820</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1097/MLR.0b013e3180618b55</pub-id><pub-id pub-id-type="medline">17712252</pub-id></nlm-citation></ref></ref-list><app-group><supplementary-material id="app1"><label>Multimedia Appendix 1</label><p>Population pyramid demonstrating the age and sex distribution of enrolled participants (N=122).</p><media xlink:href="formative_v10i1e94551_app1.png" xlink:title="PNG File, 717 KB"/></supplementary-material><supplementary-material id="app2"><label>Multimedia Appendix 2</label><p>Baseline age and sex distribution of enrolled participants (N=122).</p><media xlink:href="formative_v10i1e94551_app2.pdf" xlink:title="PDF File, 33 KB"/></supplementary-material><supplementary-material id="app3"><label>Multimedia Appendix 3</label><p>Sex-stratified changes in BMI and waist circumference.</p><media xlink:href="formative_v10i1e94551_app3.pdf" xlink:title="PDF File, 33 KB"/></supplementary-material></app-group></back></article>